



TMC LIFE SCIENCES BERHAD
Company no. 624409-A
(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT
FOR THE FINANCIAL QUARTER ENDED
31 AUGUST 2012

Contact

No 11 Jalan Teknologi
Taman Sains Selangor 1
PJU 5, Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111
Fax: +603 6287 1212

www.tmclife.com

TMC LIFE SCIENCES BERHAD (624409-A)

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 AUGUST 2012

	Individual Quarter		Cumulative Period	
	Current Quarter Unaudited 31.08.2012 RM'000	Comparative Quarter Unaudited 31.08.2011 RM'000	Current Year-to-date Unaudited 31.08.2012 RM'000	Comparative Year-to-date Unaudited 31.08.2011 RM'000
Continuing Operations				
Revenue	16,402	12,492	16,402	12,492
Cost of Sales	(5,564)	(4,214)	(5,564)	(4,214)
Gross profit	10,838	8,278	10,838	8,278
Other operating income	114	495	114	495
Operating expenses	(8,892)	(8,122)	(8,892)	(8,122)
Profit from operations	2,060	651	2,060	651
Depreciation	(1,856)	(1,824)	(1,856)	(1,824)
Interest income	71	3	71	3
Finance costs	(127)	(666)	(127)	(666)
Profit / (Loss) before tax	148	(1,836)	148	(1,836)
Taxation	(34)	-	(34)	-
Profit / (Loss) after taxation from continuing operations	114	(1,836)	114	(1,836)
Discontinued Operations				
Loss from discontinued operations	(526)	(498)	(526)	(498)
Gain on disposal of a subsidiary	3,199	-	3,199	-
Profit / (Loss) after taxation	2,787	(2,334)	2,787	(2,334)
Other comprehensive income :-				
Exchange differences on translation of foreign operations	5	16	5	16
Total comprehensive income / (loss) for the period	2,792	(2,318)	2,792	(2,318)
Profit / (Loss) attributable to :-				
Owners of the parent	2,787	(2,334)	2,787	(2,334)
Non-controlling interest	-	-	-	-
	2,787	(2,334)	2,787	(2,334)
Total comprehensive income / (loss) attributable to :-				
Owners of the parent	2,792	(2,318)	2,792	(2,318)
Non-controlling interest	-	-	-	-
	2,792	(2,318)	2,792	(2,318)
Earnings per share (sen)				
- Basic	0.38	(0.39)	0.38	(0.39)
- Diluted	0.27	N/A	0.27	N/A

Note: N/A denotes Not Applicable

The unaudited condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 May 2012 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD (624409-A)
(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE QUARTER ENDED 31 AUGUST 2012**

	Attributable to owners of the parent				Total attributable to owners of the parents RM'000	Non- controlling interest RM'000	Total equity RM'000	
	Non-distributable			Distributable				
	Share capital RM'000	Share premium RM'000	Warrants reserve RM'000	Foreign exchange translation RM'000				Accumulated losses RM'000
Balance at 1 June 2012	80,237	33,159	28,083	10	(21,300)	120,189	-	120,189
Conversion of warrants	*	*	*	-	-	-	-	-
Total comprehensive income	-	-	-	5	2,787	2,792	-	2,792
Balance at 31 August 2012	80,237	33,159	28,083	15	(18,513)	122,981	-	122,981
Balance at 1 June 2011	60,178	21,752	-	7	(15,895)	66,042	-	66,042
Total comprehensive loss	-	-	-	16	(2,334)	(2,318)	-	(2,318)
Balance at 31 August 2011	60,178	21,752	-	23	(18,229)	63,724	-	63,724

* amount is insignificant

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 May 2012 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD (624409-A)

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**AS AT 31 AUGUST 2012**

	As At 31.08.2012 Unaudited RM'000	As At 31.05.2012 Audited RM'000
Non-current assets		
Property, plant and equipment	112,847	123,278
Total non-current assets	112,847	123,278
Current assets		
Inventories	2,643	2,778
Trade and other receivables	11,110	11,673
Current tax assets	1,392	1,760
Cash and cash equivalents	16,340	14,303
Assets classified as held for sale	8,643	-
Total current assets	40,128	30,514
TOTAL ASSETS	152,975	153,792
Equity attributable to owners of the parent		
Share capital	80,237	80,237
Accumulated losses	(18,513)	(21,300)
Reserves	61,257	61,252
	122,981	120,189
Non-controlling interest	-	-
TOTAL EQUITY	122,981	120,189
Non-current liabilities		
Borrowings	7,349	7,401
Other deferred liabilities	2,968	2,968
Trade and other payables	-	2,908
Total non-current liabilities	10,317	13,277
Current liabilities		
Trade and other payables	18,252	20,088
Borrowings	235	231
Current tax liabilities	7	7
Liabilities classified as held for sale	1,183	-
Total current liabilities	19,677	20,326
TOTAL EQUITY AND LIABILITIES	152,975	153,792
Net assets per share (RM)	0.15	0.15

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 May 2012 and the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD (624409-A)

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE QUARTER ENDED 31 AUGUST 2012**

	Current Year-to-date 31.08.2012 RM'000	Comparative Year-to-date 31.08.2011 RM'000
Cash flows from operating activities		
Profit / (Loss) before tax	148	(1,836)
Adjustment for non-cash flow items :-		
Non-cash items	1,856	1,824
Interest paid	127	666
Interest income	(71)	(3)
Operating profit before changes in working capital	2,060	651
Changes in working capital		
Net change in current assets	236	(238)
Net change in current liabilities	(382)	(1,199)
Net cash flows from operating activities	1,914	(786)
Interest paid	(126)	(666)
Income tax refunded / (paid)	60	(113)
Net cash flows from operating activities	1,848	(2,764)
Cash flows from investing activities		
Acquisition of property plant and equipment	(531)	(56)
Net cash inflow from disposal of subsidiaries	683	-
Interest received	71	3
	223	(53)
Cash flows from financing activities		
Drawdown of term loans	-	5,000
Repayment of term loans	(44)	(1,773)
Repayment of hire purchase	(4)	(4)
	(48)	3,223
Net change in cash & cash equivalents	2,023	2,384
Cash & cash equivalents at beginning of the financial period	14,303	(1,810)
Exchange rate effects	14	16
Cash & cash equivalents at end of the financial period	16,340	590
Cash & cash equivalents at end of the financial period		
Short term deposits	853	418
Cash and bank balances	15,487	2,129
	16,340	2,547
Overdraft	-	(1,957)
	16,340	590

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 May 2012 and the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE QUARTER ENDED 31 AUGUST 2012**

A EXPLANATORY NOTES PURSUANT TO FINANCIAL REPORTING STANDARD (“FRS”)

A1 BASIS OF PREPARATION

The interim financial statements for the period ended 31 August 2012 have been prepared in accordance with MFRS 134 Interim Financial Reporting and paragraph 9.22 of the Listing Requirement of Bursa Malaysia Securities Berhad. These interim financial statements also comply with IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board. For the period up to and including the year ended 31 May 2012, the Group prepared its financial statements in accordance with Financial Reporting Standards (“FRS”).

The interim financial statements are the Group's first MFRS interim financial statements for part of the period covered by the Group's first MFRS annual financial statements for the year ending 31 May 2013. MFRS 1 First-Time Adoption of Malaysian Financial Reporting Standards has been applied.

The explanatory notes attached to these interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 May 2012.

The MFRS are effective for the Group from 1 June 2012 and the date of transition to the MFRS framework for the purpose of the first MFRS compliant Condensed Report is 1 January 2012. At that transition date, the Group reviewed its accounting policies and considered the transitional opportunities under MFRS1. An explanation of how the transition from FRS to MFRS has affected the Group's financial position, financial performance and cash flows is set out in Note A2 below. The transition from FRS to MFRS has not had a material impact on the statement of cash flows.

A2 SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF MFRS 1

The audited financial statements of the Group for the year ended 31 May 2012 were prepared in accordance with FRS. Except for certain differences, the requirements under FRS and MFRS are similar. The significant accounting policies adopted in preparing these interim financial statements are consistent with those of the audited financial statements for the year ended 31 May 2012 except as discussed below:

Business Combinations

MFRS 1 provides the option to apply MFRS 3 Business Combinations, prospectively from the date of transition or from a specific date prior to the date of transition. This provides relief from full retrospective application of MFRS 3 which would require restatement of all business combinations prior to the date of transition.

Acquisition before date of transition

The Group has elected to apply MFRS 3 prospectively from the date of transition. In respect of acquisitions prior to the date of transition,

- (a) The classification of former business combinations under FRS is maintained;
- (b) There is no re-measurement of original fair values determined at the time of business combination (date of acquisition); and
- (c) The carrying amount of goodwill recognised under FRS is not adjusted.

TMC LIFE SCIENCES BERHAD (624409-A)

(Incorporated in Malaysia)

A3 MFRS, AMENDMENTS TO MFRS AND IC INTERPRETATION ISSUED BUT NOT YET EFFECTIVE

At the date of authorisation of these interim financial statements, the following MFRS, Amendments to MFRS and IC Interpretation were issued but not yet effective and have not been applied by the Group:

MFRS 9	Financial instruments (IFRS 9 issued by IASB in November 2009 and October 2010)
MRFS 10	Consolidated financial statements
MFRS 11	Joint arrangements
MRFS 12	Disclosure of interests in other entities
MFRS 13	Fair value measurement
MFRS 119	Employee benefits
MFRS 127	Separate financial statements
MFRS 128	Investment in associates and joint ventures
Amendments to MFRS 1	Government loans
Amendments to MFRS 1	Annual improvement 2009 - 2011 cycle
Amendments to MFRS 7	Disclosures - offsetting financial assets and financial liabilities
Amendments to MFRS 10, 11 and 12	Consolidated financial statements, joint arrangements and disclosure of interests in other entities: transition guidance
Amendments to MFRS 101	Presentation of items of other comprehensive income
Amendments to MFRS 116	Annual improvement 2009 - 2011 cycle
Amendments to MFRS 132	Annual improvement 2009 - 2011 cycle
Amendments to MFRS 132	Offsetting financial assets and financial liabilities
Amendments to MFRS 134	Annual improvement 2009 - 2011 cycle
IC Interpretation 2	Annual improvement 2009 - 2011 cycle
IC Interpretation 20	Stripping costs in the production phase of a surface mine

A4 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was not qualified.

A5 SEASONALITY OR CYCLICALITY OF OPERATIONS

The business of the Group is not significantly affected by any seasonal or cyclical factors.

A6 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A5 CHANGE IN ESTIMATES

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial quarter under review.

A6 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review other than the allotment of 2 new ordinary shares of RM0.10 each pursuant to exercise of 2 Warrants during the quarter under review.

TMC LIFE SCIENCES BERHAD (624409-A)

(Incorporated in Malaysia)

A7 DIVIDENDS PAID

No dividend was paid during the financial period ended 31 August 2012.

A8 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and currently is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital.

A9 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

Except for those disclosed in note B6, there were no other material event subsequent to 31 August 2012 and up to the date of this report.

A10 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter other than the following:

- (a) On 8 August 2012, the Company and its wholly-owned subsidiary, TMC Women's Specialist Holdings Sdn. Bhd. ("TWSH") entered into a Shares Sale and Purchase Agreement with Carl Corryntan Holdings Sdn. Bhd. ("Purchaser") to dispose to the Purchaser, the entire equity interest, comprising 100 ordinary shares of RM1 each in Tropicana Medical Centre (Penang) Sdn. Bhd. ("TMCP"), for a cash consideration of RM2,600,000 ("Disposal of TMCP").

The Disposal of TMCP is expected to be completed by 4th Quarter 2012.

- (b) On 16 August 2012, the Company entered into a Share Sale Agreement ("SSA") with Cryocord Holdings Sdn. Bhd. ("Cryocord"), a company incorporated in Malaysia, to dispose to Cryocord the entire issued and paid up share capital of one million (1,000,000) ordinary shares of RM1 each in the capital of Stemtech International Sdn. Bhd. ("Stemtech"), a wholly-owned subsidiary of the Company, for a total consideration of RM800,000 ("Disposal of Stemtech"). The Disposal was completed on 29 August 2012. Upon completion, Stemtech ceased to be a subsidiary of the Group.

A11 DISCONTINUED OPERATIONS AND GAIN ON DISPOSAL OF SUBSIDIARIES

As disclosed in note A10 above, for the Disposal of TMCP, Disposal of Property (see note B6 (1)) and Disposal of Stemtech (hereinafter referred to as "Disposals"), in accordance with MFRS 5: Non-current Assets Held for Sale and Discontinued Operations, the Disposals are classified as Assets and Liabilities held for sale/discontinued operations as at 31 August 2012 and the comparative condensed consolidated statement of profit or loss and other comprehensive income has been re-presented to show the discontinued operations separately from continuing operations.

The loss attributable to the discontinued operations are as follows:

	Individual Quarter	
	31.08.2012	31.08.2011
	RM'000	RM'000
Revenue	588	727
Cost of sales	(367)	(439)
Gross profit	221	288
Other operating income	18	1
Operating expenses	(681)	(700)
Loss from operations	(442)	(411)
Depreciation	(84)	(87)
Loss before tax	(526)	(498)
Taxation	-	-
Loss after taxation	(526)	(498)

TMC LIFE SCIENCES BERHAD (624409-A)
(Incorporated in Malaysia)

A11 DISCONTINUED OPERATIONS AND GAIN ON DISPOSAL OF SUBSIDIARIES (Cont'd)

The major classes of assets and liabilities held for sale for Disposal of TMCP and Disposal of Property as at 31 August 2012 are as follows:

	31.08.2012 RM'000
ASSETS	
Property, plant and equipment	7,966
Inventories	71
Trade and other receivables	33
Current tax assets	275
Cash and cash equivalents	298
Assets classified as held for sale	<u>8,643</u>
LIABILITIES	
Trade and other payables	<u>1,183</u>
Liabilities classified as held for sale	<u>1,183</u>

The Disposal of Stemtech had the following effects on the financial position of the Group:

	31.08.2012 RM'000
Net liabilities arising from Disposal of Stemtech	(2,399)
Gain on disposals	<u>3,199</u>
Cash considerations	800
Less cash and cash equivalent disposed off	<u>(117)</u>
Net cash inflow from disposal of subsidiaries	<u>683</u>

A12 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

The Company has provided corporate guarantees to licensed financial institutions for banking facilities, and suppliers amounting to RM66.06 million and RM2.55 million respectively. The guarantees were granted for the benefit of the Company's subsidiaries and invested company. Arising from this, the Company is contingently liable for the amount utilized by its subsidiaries and invested company of approximately RM8.4 million as at 31 August 2012.

A13 CAPITAL COMMITMENTS

There was no capital commitment not provided for in the financial quarter as at 31 August 2012.

A14 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the current financial quarter under review.

**NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE QUARTER ENDED 31 AUGUST 2012**

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD
("BURSA SECURITIES")**

B1 REVIEW OF THE PERFORMANCE OF THE GROUP

Analysis of performance

Review of results for the financial quarter

	3 months ended	
	31.08.2012	31.08.2011
	RM'000	RM'000
Revenue	16,402	12,492
Profit / (Loss) before taxation	148	(1,836)

Revenue rose 31% compared to the previous corresponding quarter mainly due to high patient load, both local and foreign, with increased bed capacity and more variety of disciplines offered.

The Group recorded profit before tax for the current quarter as compared to loss before tax in the previous corresponding quarter. The improvement was mainly attributable to higher revenue achieved coupled with reduction in interest expenses from repayment of RM39.0 million bank borrowings in end December 2011.

Material factors affecting the earnings and / or revenue of the Group

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of doctors practicing in our hospitals and variety of facilities and services offered by the hospitals.

B2 MATERIAL CHANGE IN PROFIT BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER

	3 months ended	
	31.08.2012	31.05.2012
	RM'000	RM'000
Revenue	16,402	18,403
Profit before taxation	148	1,624

Revenue dropped by RM2.0 million or 11% compared to the immediate preceding quarter. The Group experienced lower revenue from generally low admission numbers in Ramadan month and Chinese 'hungry ghost' festival during the quarter.

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 31 MAY 2013

The Group continues to focus on building the business through greater market awareness programs in both the domestic and international market, increasing the number of specialists and sub-specialists medical consultants. The Board of Directors is of the opinion that the prospects of the Group remain positive and the performance will continue to improve in tandem with increasing hospital capacity and marketing activities.

TMC LIFE SCIENCES BERHAD (624409-A)
(Incorporated in Malaysia)

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

Not applicable.

B5 TAXATION

	3 months ended	
	31.08.2012 RM'000	31.08.2011 RM'000
In respect of current financial year		
- income taxation	34	-
- deferred taxation	-	-
	<u>34</u>	<u>-</u>
Under / (over) provision in respect of prior period		
- income taxation	-	-
- deferred taxation	-	-
	<u>-</u>	<u>-</u>
	<u>34</u>	<u>-</u>

The effective tax rate of the Group's current tax charge for the current period under review was lower than the statutory tax rate mainly due to the losses made coupled with the tax exemption pursuant to the BioNexus incentive enjoyed by a subsidiary who has been granted the BioNexus Status by the Malaysian Biotechnology Corporation Sdn Bhd.

B6 STATUS OF CORPORATE PROPOSAL

(1) On 8 August 2012, the Company and its wholly-owned subsidiary, TMC Women's Specialist Holdings Sdn. Bhd. ("TWSH") entered into a Shares Sale and Purchase Agreement with Carl Corryntan Holdings Sdn. Bhd. ("Purchaser") to dispose to the Purchaser, the entire equity interest, comprising 100 ordinary shares of RM1 each in Tropicana Medical Centre (Penang) Sdn. Bhd. ("TMCP"), for a cash consideration of RM2,600,000 ("Disposal of TMCP").

On the same date, the Company also announced that TMC Properties Sdn. Bhd. ("TMC Prop"), a wholly-owned subsidiary, entered into a Property Sale and Purchase Agreement with the Purchaser to dispose all that piece of freehold land held under GRN 62532 for Lot No. 4778 Section 5, Bandar Georgetown, Daerah Timor Laut, Penang together with a four (4) storey building [hereinafter collectively referred to as the "Property"] on an "as-is-where-is basis" together with all the fixtures, fittings, furniture, plant and equipment and machinery (excluding TMCP's assets) contained in the Property with vacant possession free from all encumbrances, for a cash consideration of RM11,000,000 ("Disposal of Property").

The Disposal of TMCP and Disposal of Property are expected to be completed by 4th Quarter of 2012.

(2) On 16 August 2012, the Company entered into a Share Sale Agreement ("SSA") with Cryocord Holdings Sdn. Bhd. ("Cryocord"), a company incorporated in Malaysia, to dispose to Cryocord the entire issued and paid up share capital of one million (1,000,000) ordinary shares of RM1 each in the capital of Stemtech International Sdn. Bhd. ("Stemtech"), a wholly-owned subsidiary of the Company, for a total consideration of RM800,000 ("Disposal of Stemtech"). Disposal of Stemtech was completed on 29 August 2012. Upon completion, Stemtech ceased to be a subsidiary of the Group.

(3) Further to the announcement made on 19 September 2011 pertaining to the Memorandum of Understanding ("MoU") with Berjaya Corporation Berhad and Viet Ha Corporation, on 14 September 2012, the Company announced that the parties to the MoU have mutually agreed to extend the duration of the MoU for a further period of twelve (12) months from 18 September 2012 until 17 September 2013.

TMC LIFE SCIENCES BERHAD (624409-A)
(Incorporated in Malaysia)

B6 STATUS OF CORPORATE PROPOSAL (Cont'd)

(4) Status of Utilisation of Proceeds

The status of utilisation of the gross proceeds raised from Rights Issue as at 15 October 2012 is as follows:

	Proposed Utilisation RM'000	Actual Utilisation RM'000	Intended timeframe for Utilisation	Deviation Amount RM'000	Explanation
Repayment of borrowings	38,960	38,960	Within 18 months	-	
Capital expenditure	10,000	2,543	Within 18 months	7,457	Note
Working capital	10,218	10,218	Within 18 months	-	
Estimated expenses for the Rights Issue	1,000	1,000	Within 3 months	-	
Total	60,178	52,721		7,457	

Note: The proceeds will be utilised within the estimated timeframe.

B7 BORROWINGS

The Group's borrowings as at 31 August 2012 are as follows:-

	Long Term RM'000	Short Term RM'000	Total RM'000
Secured	7,349	235	7,584

B8 MATERIAL LITIGATION

There were no material litigations as at the date of this report.

B9 DIVIDENDS

The Board does not recommend the payment of any dividend for the current financial quarter under review.

TMC LIFE SCIENCES BERHAD (624409-A)
(Incorporated in Malaysia)

B10 EARNINGS/ (LOSS) PER SHARE (EPS/LPS)

	3 months ended	
	31.08.2012	31.08.2011
(a) Basic EPS		
Net profit / (loss) attributable to owners of the parent (RM'000)	<u>2,787</u>	<u>(2,334)</u>
Weighted average number of ordinary shares outstanding (000)	<u>740,821</u>	<u>601,780</u>
EPS / (LPS) (sen)		
- Basic	<u>0.38</u>	<u>(0.39)</u>
(b) Diluted EPS		
Net profit / (loss) attributable to owners of the parent (RM'000)	<u>2,787</u>	<u>(2,334)</u>
Weighted average number of ordinary shares outstanding (000)	<u>740,821</u>	<u>601,780</u>
Effect of dilution ('000)	<u>278,083</u>	<u>NA</u>
Adjusted weighted average number of shares ('000)	<u>1,018,904</u>	<u>601,780</u>
EPS (sen)		
- Diluted	<u>0.27</u>	<u>NA</u>

Diluted EPS is calculated by dividing the profit attributable to owners of the parent by the weighted average of ordinary shares outstanding during the financial period ended 31 August 2012, adjusted to assume the conversion of dilutive potential ordinary shares.

B11 REALISED AND UNREALISED PROFITS/(LOSSES)

	31.08.2012	31.05.2012
	RM'000	RM'000
Total accumulated losses:		
- realised	(15,365)	(18,223)
- unrealised	<u>(3,148)</u>	<u>(3,077)</u>
As at 31 August 2012 / 31 May 2012	<u>(18,513)</u>	<u>(21,300)</u>

B12 AUTHORISED FOR ISSUE

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 15 October 2012.